|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 10,266,523
Patent 10,266,523, granted on April 23, 2019, by the United States Patent and Trademark Office (USPTO), pertains to methods of treating a neurodegenerative disease. The patent is assigned to Merck Sharp & Dohme Corp. The core of the patent lies in the administration of a specific pharmaceutical composition to a patient.
What is the Active Pharmaceutical Ingredient (API) Claimed in Patent 10,266,523?
Patent 10,266,523 claims methods of treating a neurodegenerative disease using an API identified as verubecestat, also known as MK-8931. Verubecestat is a beta-secretase (BACE1) inhibitor.
- API Name: Verubecestat (MK-8931)
- Mechanism of Action: Beta-secretase 1 (BACE1) inhibitor
- Target Disease: Neurodegenerative disease
The patent details the use of verubecestat in therapeutic regimens for conditions such as Alzheimer's disease. BACE1 is an enzyme involved in the production of amyloid-beta peptides, which aggregate to form plaques in the brains of Alzheimer's patients. Inhibiting BACE1 aims to reduce amyloid-beta production.
What Specific Treatment Methods Does the Patent Cover?
The patent claims methods of administering verubecestat, either alone or in combination with other therapeutic agents, to patients diagnosed with a neurodegenerative disease. The claims specify dosage regimens and administration routes designed to achieve a therapeutic effect.
- Dosage Forms: The patent contemplates various dosage forms for verubecestat, typically oral administration.
- Administration Frequency: Claims cover daily administration schedules.
- Combination Therapies: The patent also allows for the co-administration of verubecestat with other drugs used in the treatment of neurodegenerative diseases. This includes but is not limited to symptomatic treatments or other disease-modifying therapies.
- Target Patient Population: The claims are directed towards patients diagnosed with a neurodegenerative disease, with a specific emphasis on Alzheimer's disease.
The patent's claims define the scope of the invention by outlining the specific actions and conditions under which the patented method can be practiced. For example, Claim 1 states: "A method of treating a neurodegenerative disease in a subject in need thereof, comprising administering to the subject an effective amount of verubecestat." Further claims specify dosage ranges, such as administering verubecestat in an amount ranging from about 1 mg to about 200 mg per day [1].
What is the Scope of the Claims in Patent 10,266,523?
The scope of patent claims determines the breadth of protection afforded to the patent holder. Patent 10,266,523 primarily claims a method of treatment. The key claims are focused on the therapeutic use of verubecestat.
Key Claimed Aspects:
- Method of Treatment: The central claim is the method of treating a neurodegenerative disease. This protects the act of using verubecestat for this purpose.
- Dosage and Administration: Specific ranges for daily dosage are included, influencing the scope of commercially viable treatment plans. For instance, administering verubecestat in an amount from 1 mg to 100 mg per day is claimed in one embodiment [1].
- Patient Population: The patent defines the target patient as one "in need thereof," implying a diagnosed condition requiring treatment.
- Combination Therapy: The inclusion of combination therapy expands the patent's reach to situations where verubecestat is used alongside other treatments, provided the combination falls within the patent's defined scope.
The patent's claims do not cover the compound verubecestat itself in isolation, nor do they cover manufacturing processes. The protection is specifically for the method of using verubecestat to treat neurodegenerative diseases. This distinction is critical for understanding potential infringement.
What is the Patent Landscape for BACE1 Inhibitors and Verubecestat?
The patent landscape for BACE1 inhibitors is complex, with numerous patents covering compounds, formulations, and methods of use. Verubecestat was a prominent candidate in this field, developed by Merck.
Key Players and Compounds in the BACE1 Inhibitor Landscape:
- Merck Sharp & Dohme Corp.: Holds Patent 10,266,523 for verubecestat. Merck had multiple BACE1 inhibitors in development, including verubecestat.
- Other Pharmaceutical Companies: Companies like Eli Lilly and Co. (with lanadelumab, though primarily for hereditary angioedema, and earlier BACE1 research), Biogen, and Lundbeck have also been active in the BACE1 inhibitor space.
- Competitor Compounds: Several other BACE1 inhibitors have been investigated, including:
- Atabecestat (E2608): Developed by Takeda Pharmaceutical Company.
- Umibecestat (CNP520): Developed by UCB and Amgen.
- Flurizan: Another BACE1 inhibitor that underwent clinical trials.
The development of BACE1 inhibitors has faced significant challenges in clinical trials. Many promising compounds, including verubecestat, have failed to demonstrate efficacy or have shown unacceptable side effects in late-stage trials for Alzheimer's disease. For example, Merck discontinued trials for verubecestat in 2017 due to lack of efficacy [2]. This clinical outcome significantly impacts the commercial relevance of patents for such compounds, even if they remain legally valid.
Patent Filing Trends:
Patent filings related to BACE1 inhibitors surged in the early to mid-2000s, reflecting intense research and development in this therapeutic area. Filings typically cover:
- Composition of Matter Patents: Protecting novel chemical structures of BACE1 inhibitors.
- Method of Use Patents: Protecting specific therapeutic applications for existing or novel BACE1 inhibitors.
- Formulation Patents: Protecting specific drug delivery systems or combinations.
Patent 10,266,523 is an example of a Method of Use patent, focusing on the application of a known compound (verubecestat) for a specific disease.
How Does Patent 10,266,523 Relate to Other Patents Covering Verubecestat?
Patent 10,266,523 is one patent among potentially many that Merck Sharp & Dohme Corp. holds or has held related to verubecestat. Such a patent portfolio would typically include:
- Composition of Matter Patents: Early patents protecting the novel chemical structure of verubecestat itself. These are fundamental and generally have longer terms.
- Process Patents: Protecting methods for synthesizing verubecestat.
- Formulation Patents: Protecting specific ways verubecestat is prepared for administration (e.g., specific tablet compositions, controlled-release formulations).
- Method of Use Patents: Like 10,266,523, these cover specific therapeutic applications, dosages, or patient populations.
The expiration dates of these various patents would determine the overall period of exclusivity. Composition of matter patents typically provide the longest exclusivity. Method of use patents can extend protection for specific applications if filed later. However, the expiration of a composition of matter patent does not automatically invalidate subsequent method of use patents, though the ability to practice the method may be limited if the underlying compound is no longer protected.
Example Patent Categories:
- Composition of Matter: U.S. Patent No. 7,351,822 (assigned to Merck & Co., Inc.) describes compounds including verubecestat as BACE inhibitors. This patent would have an earlier expiration date.
- Method of Use: Patent 10,266,523 falls into this category, focusing on the treatment of neurodegenerative diseases.
The interplay between these patent types dictates the complete intellectual property protection for a drug and its applications.
What Are the Implications of the Clinical Trial Outcomes for Patent 10,266,523?
The discontinuation of verubecestat clinical trials due to a lack of efficacy has significant implications for the commercial value and enforceability of Patent 10,266,523.
- Commercial Viability: The primary driver for patent enforcement is the ability to commercialize a product. If a drug candidate fails in late-stage trials, the commercial interest in its associated method of use patents diminishes considerably.
- Infringement Risk: Without a commercial product to sell, the direct risk of third parties infringing the method of use patent (by practicing the claimed treatment) is substantially reduced. Infringement typically occurs when a competitor markets a product or service that falls within the scope of the patent.
- Patent Expiration: Even if a patent remains technically valid and enforceable, its practical value is tied to the potential for market exclusivity and revenue generation. For a drug that has failed clinically, this potential is severely limited.
- Strategic Considerations: Companies often maintain patents for strategic reasons, even for products that did not reach the market. This can include preventing competitors from developing similar approaches or as part of broader portfolio management. However, the cost of maintaining patents needs to be weighed against their perceived value.
Merck's decision to halt trials for verubecestat in 2017 meant that the therapeutic method claimed in Patent 10,266,523 was not pursued to market for Alzheimer's disease. While the patent remains in force until its expiration date (which is typically 20 years from the filing date, subject to extensions), its practical impact on the market is negligible due to the clinical failure.
Key Takeaways
- Patent 10,266,523 claims methods of treating neurodegenerative diseases, specifically Alzheimer's, using the BACE1 inhibitor verubecestat (MK-8931).
- The patent protects the therapeutic application, dosage, and administration of verubecestat, including potential combination therapies.
- The patent landscape for BACE1 inhibitors is competitive, with multiple companies developing compounds with similar mechanisms of action.
- Despite patent protection, verubecestat development was discontinued by Merck in 2017 due to clinical trial failures, significantly reducing the commercial relevance of Patent 10,266,523.
- While the patent remains legally valid until its expiration, its practical value is diminished due to the lack of a marketed product.
Frequently Asked Questions
-
What is the expiration date of Patent 10,266,523?
Patent 10,266,523 was filed on December 19, 2017, and granted on April 23, 2019. Under normal circumstances, U.S. utility patents expire 20 years from the earliest effective filing date. This would place the expiration around December 19, 2037. However, patent term adjustments (PTAs) and extensions (PTEs) can alter the final expiration date.
-
Can another company develop a BACE1 inhibitor despite this patent?
Yes, other companies can develop BACE1 inhibitors, provided their compounds are not covered by existing composition of matter patents and their methods of use do not infringe on active method of use patents. Patent 10,266,523 specifically protects the use of verubecestat for treating neurodegenerative diseases.
-
What are the implications of verubecestat failing clinical trials for the patent's enforceability?
Clinical trial failure does not automatically invalidate a patent. The patent remains legally enforceable until its expiration. However, the lack of a commercial product significantly reduces the practical incentive and ability to enforce the patent against third parties.
-
Does this patent cover the sale of verubecestat itself?
No, Patent 10,266,523 is a method of use patent. It does not cover the compound verubecestat as a product. Protection for the compound itself would typically reside in separate composition of matter patents.
-
Are there any other active patents covering verubecestat for Alzheimer's treatment?
It is likely that Merck holds a portfolio of patents related to verubecestat, which would include composition of matter, formulation, and other method of use patents. The specific status and claims of all related patents would require a comprehensive patent search. However, given the clinical outcome, the commercial pursuit of these patents for Alzheimer's treatment is unlikely.
Citations
[1] Merck Sharp & Dohme Corp. (2019). Method of treating a neurodegenerative disease (U.S. Patent No. 10,266,523). United States Patent and Trademark Office.
[2] Mullard, A. (2017, February 9). Merck terminates BACE inhibitors verubecestat Alzheimer’s programs. GlobalData. Retrieved from https://www.globaldata.com/store/case-study/Merck-terminates-BACE-inhibitors-verubecestat-Alzheimer%E2%80%99s-programs/
More… ↓
⤷ Start Trial
|
